Merck announced plans to pursue regulatory approval for two new combination regimens pairing its HIF-2α inhibitor Welireg with pembrolizumab (Keytruda) and with lenvatinib (Lenvima) in kidney cancer, following recent trial readouts. The company presented Phase 2/3 results that supported movement into broader indications despite outstanding questions about overall survival benefit. Merck’s filings aim to position Welireg as a backbone for combination regimens in clear cell renal cell carcinoma. The company emphasized the potential to expand the drug’s commercial footprint if regulators accept surrogate endpoints or disease‑free survival measures in adjuvant settings. The push reflects intensified competition in renal oncology and will test regulators’ interpretation of composite and intermediate endpoints in approving combination regimens.